Dynamic individualized risk profiling for patients receiving CD19 CAR T-cell therapy
Official title: Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
Run by University of Zurich · NCT07472972 · Data updated 2026-11-12
This project tries a combined blood, imaging, and lab test to predict which adults with relapsed or refractory B‑cell lymphoma will do well after CD19 CAR T‑cell therapy.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Zurich Academic / other |
| Drugs / interventions | CAR T, CAR-T |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Status | Recruiting |
| Started | June 20, 2025 |
| Main results expected | January 1, 2028 |
| Study ends | May 31, 2030 |
| Registry record updated | March 16, 2026 |
| Trial ID | NCT07472972 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with relapsed or refractory B‑cell lymphoma who are planned for CD19‑redirected CAR T‑cell therapy and willing to provide serial blood samples and biopsy material are ideal candidates.
✕Probably not a fit
Patients not receiving CD19 CAR T therapy, those with contraindications to CAR T infusion, or those unable or unwilling to complete the required serial sampling and visits are unlikely to benefit from this assay.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
INTeRCePT 2.0 is a prospective observational feasibility study enrolling adults with relapsed or refractory B‑cell lymphomas who are scheduled to receive standard‑of‑care CD19‑redirected CAR T‑cell therapy. The study collects serial data across five components—circulating tumor DNA by CAPP‑seq, peripheral blood inflammation markers (InflaMIX), PET‑CT imaging metrics, immune cell profiling by flow cytometry, and ECOG performance status—to build a dynamic individualized risk profile for each patient. The primary objective is feasibility, measured as the rate of complete INTeRCePT assay profiling with a co‑primary endpoint of completing the profile by 38 days after CAR T infusion. If feasible, the longitudinal assay is intended to enable earlier detection of high‑risk patients to guide more personalized treatment decisions in future interventional work.
Why it matters
Potential benefit: If successful, the assay could identify patients at high risk of early CAR T failure so clinicians can consider earlier or intensified treatment strategies.
How similar studies have gone: Individual components such as ctDNA and PET imaging have shown promise in predicting CAR T outcomes in prior work, but the integrated five‑component longitudinal INTeRCePT assay is novel and remains unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent before registration and prior to any trial specific procedures * Participants ≥ 18 years of age * Diagnosis of relapse/refractory B-cell lymphoma according to WHO 2022 classification * Measurable disease per response criteria specific to the disease e.g. per Lugano 2014 criteria * Patients planned for CD19-redirected CAR T cell therapy according to clinical standard of care * Patients who are willing to donate peripheral blood and biopsy material at indicated clinical visits Exclusion Criteria: * Any condition, which precludes initiation of CD19-redirected CAR T cell therapy (e.g. breast feeding, pregnancy, infections, etc.) as judged by the treating physician * Any coexisting medical or psychological condition that would preclude participation in the required study procedures, as judged by the treating physician * Unwillingness or inability to comply with the protocol
Where it's running
-
Universityhospital Zurich, Department of Medical Oncology and Hematology
Zurich, Canton of Zurich, Switzerland Recruiting
Study contacts
- Study coordinator: Thorsten Zenz, Prof. Dr. med.
- Email: thorsten.zenz@usz.ch
- Phone: +41 44 255 38 99
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma
This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.
-
CD19/CD22 CAR-T as first-line consolidation for follicular lymphoma
This trial tests whether CAR-T cells targeting CD19 and CD22 can be used as a first-line consolidation therapy for people with follicular lymphoma to see if it improves outcomes.
-
Remote rehabilitation for people receiving CAR-T cell therapy
This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.
-
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.